Neurosense Therapeutics Ltd (NRSN)

Apr 24, 2025, 9:09 AM EDT - 4 days ago

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

Apr 9, 2025, 8:30 AM EDT - 19 days ago

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

Apr 7, 2025, 5:14 PM EDT - 20 days ago

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

Apr 4, 2025, 9:10 AM EDT - 24 days ago

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

Mar 17, 2025, 8:30 AM EDT - 6 weeks ago

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

Jan 6, 2025, 9:00 AM EST - 4 months ago

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

Dec 23, 2024, 9:00 AM EST - 4 months ago

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

Dec 18, 2024, 10:25 AM EST - 4 months ago

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

Dec 11, 2024, 9:25 AM EST - 4 months ago

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

Dec 4, 2024, 8:30 AM EST - 5 months ago

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

Dec 2, 2024, 8:30 AM EST - 5 months ago

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

Nov 21, 2024, 9:20 AM EST - 5 months ago

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

Oct 28, 2024, 8:30 AM EDT - 6 months ago

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

Oct 24, 2024, 8:30 AM EDT - 6 months ago

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

Oct 15, 2024, 9:15 AM EDT - 6 months ago

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

Oct 9, 2024, 9:00 AM EDT - 7 months ago

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

Oct 7, 2024, 9:00 AM EDT - 7 months ago

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

Sep 24, 2024, 9:05 AM EDT - 7 months ago

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

Sep 24, 2024, 9:00 AM EDT - 7 months ago

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

Aug 30, 2024, 4:30 PM EDT - 8 months ago

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Aug 7, 2024, 2:00 PM EDT - 9 months ago

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

Aug 1, 2024, 9:15 AM EDT - 9 months ago

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

Jul 9, 2024, 9:27 AM EDT - 10 months ago

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

Jul 2, 2024, 12:34 PM EDT - 10 months ago

This cheap biotech offers investors a play on ALS if trial data continues to impress

Jul 1, 2024, 8:00 AM EDT - 10 months ago

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

Jun 24, 2024, 9:00 AM EDT - 11 months ago

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

Jun 21, 2024, 4:30 PM EDT - 11 months ago

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

May 20, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

May 14, 2024, 9:05 AM EDT - 1 year ago

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

May 7, 2024, 8:45 AM EDT - 1 year ago

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

May 2, 2024, 9:19 AM EDT - 1 year ago

NeuroSense Announces First Quarter 2024 Business Update

Apr 22, 2024, 8:30 AM EDT - 1 year ago

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

Apr 18, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

Apr 12, 2024, 8:30 AM EDT - 1 year ago

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

Apr 10, 2024, 7:16 PM EDT - 1 year ago

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

Apr 9, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

Apr 5, 2024, 9:29 AM EDT - 1 year ago

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

Feb 21, 2024, 8:30 AM EST - 1 year ago

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

Jan 30, 2024, 8:30 AM EST - 1 year ago

NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024

BIIB

Jan 9, 2024, 8:45 AM EST - 1 year ago

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts

Dec 27, 2023, 5:00 PM EST - 1 year ago

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Dec 14, 2023, 9:24 AM EST - 1 year ago

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

Dec 5, 2023, 8:00 AM EST - 1 year ago

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

Dec 4, 2023, 4:01 PM EST - 1 year ago

NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023

Nov 28, 2023, 8:45 AM EST - 1 year ago

NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update

Nov 13, 2023, 9:20 AM EST - 1 year ago

NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness

Nov 9, 2023, 9:00 AM EST - 1 year ago

NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences

Nov 6, 2023, 8:30 AM EST - 1 year ago

NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023

Nov 1, 2023, 9:00 AM EDT - 1 year ago

NeuroSense Therapeutics to Participate in BIO-Europe Fall